BUZZ-Replimune, uniQure rise after report FDA chief Makary may be ousted

Replimune

Replimune

REPL

0.00

Updates

** Shares of biotech firm Replimune REPL.O rise 4.2% to $4.24 in extended trading

** U.S. President Donald Trump is planning to fire U.S. Food and Drug Administration Commissioner Marty Makary, Reuters reports citing sources familiar with the matter

** Makary on Tuesday defended the regulator's decision to not approve REPL's drug Tudriqev for advanced skin cancer

** Last month, the health regulator declined to approve REPL's drug for the second time

** U.S.-listed shares of Dutch gene therapy developer uniQure UQ1.F close 10.4% higher on Friday following the news

** uniQure became the center of controversy when the FDA rejected its Huntington’s disease therapy, citing inadequate data and requesting a new study

** REPL down 26% YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.